Performance of the tuberculin skin test and interferon-g release assays: An update on the accuracy, cutoff stratification, and new potential immune-based approaches

Journal of Rheumatology

Volumn 41, Issue SUPPL. 91, 2014, Pages 24-31

  Goletti, Delia ^a   Sanduzzi, Alessandro ^b   Delogu, Giovanni ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Anti tumor necrosis factor therapy; Biologic agents; Igra; Latent tuberculosis; Tst; Tuberculosis

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; EPITOPE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; TUBERCULIN; BIOLOGICAL PRODUCT;

ARTICLE; AUTOIMMUNE DISEASE; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FUNCTION TEST KIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SKIN INDURATION; T LYMPHOCYTE; TUBERCULIN TEST; MASS SCREENING; SECONDARY PREVENTION;

BIOLOGICAL PRODUCTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

EID: 84899857365     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140099     Document Type: Article

References (98)

1. Barry SM, Lipman MC, Bannister B, Johnson MA, Janossy G. Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis 2003;187:243-50
2. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-73
3. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76
4. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-5
5. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9
6. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee MK. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest 2008;133:1415-20
7. Gibbs JH, Ferguson J, Brown RA, Kenicer KJ, Potts RC, Coghill G, et al. Histometric study of the localisation of lymphocyte subsets and accessory cells in human Mantoux reactions. J Clin Pathol 1984;37:1227-34
8. Platt JL, Grant BW, Eddy AA, Michael AF. Immune cell populations in cutaneous delayed-type hypersensitivity. J Exp Med 1983;158:1227-42
9. Place S, Verscheure V, de San N, Hougardy JM, Schepers K, Dirix V, et al. Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humans. Am J Respir Crit Care Med 2010;182:848-54
10. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003;3:578-90
11. Tufariello JM, Jacobs WR Jr, Chan J. Individual Mycobacterium tuberculosis resuscitation-promoting factor homologues are dispensable for growth in vitro and in vivo. Infect Immun 2004;72:515-26
12. Sarrazin H, Wilkinson KA, Andersson J, Rangaka MX, Radler L, van Veen K, et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis 2009;199:702-10
13. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, Selin MJ, Good RC, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis 1992;145:1160-6
14. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204
15. Diel R, Ernst M, Doscher G, Visuri-Karbe L, Greinert U, Niemann S, et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. Eur Respir J 2006;28:16-23
16. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501-7
17. Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med 2013;2013:601737
18. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55
19. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007;44:94-102
20. Martin-Echevarria E, Rodriguez-Zapata M, Torralba M, Fernandez JM, Moreno A, Casado JL, et al. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count. Int J Tuberc Lung Dis 2011;15:1347-52
21. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One 2012;7:e32482
22. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64
23. Whitworth HS, Scott M, Connell DW, Donges B, Lalvani A. IGRAs - The gateway to T cell based TB diagnosis. Methods 2013;61:52-62
24. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 2005;12:1311-6
25. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-104
26. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996;178:1274-82
27. Gey van Pittius NC, Sampson SL, Lee H, Kim Y, van Helden PD, Warren RM. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 2006;6:95
28. Petruccioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, et al. IFNgamma/TNFalpha specific-cells and effector memory phenotype associate with active tuberculosis. J Infect 2013;66:475-86
29. Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 2007;178:5217-26
30. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, Poccia F. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis 2006;194:984-92
31. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84
32. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009;13:84-92
33. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011;37:100-11
34. Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo D, et al. TBNET - Collaborative research on tuberculosis in Europe. Eur J Microbiol Immunol 2012;2:264-74
35. Goletti D, Carrara S, Vincenti D, Saltini C, Rizzi EB, Schinina V, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect 2006;12:544-50
36. Goletti D, Carrara S, Butera O, Amicosante M, Ernst M, Sauzullo I, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One 2008;3:e3417
37. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37:88-99
38. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75
39. Sezer I, Kocabas H, Melikoglu MA, Arman M. Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. Clin Rheumatol 2009;28:53-7
40. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1
41. Seitz M, Napierski I, Kirchner H. Depressed PPD and tetanus toxoid presentation by monocytes to T lymphocytes in patients with rheumatoid arthritis: restoration by interferon gamma. Rheumatol Int 1988;8:189-96
42. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
43. Verwilghen J, Vertessen S, Stevens EA, Dequeker J, Ceuppens JL. Depressed T-cell reactivity to recall antigens in rheumatoid arthritis. J Clin Immunol 1990;10:90-8
44. Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-9
45. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114
46. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81
47. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93
48. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907-13
49. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5
50. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90
51. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, et al. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. J Infect 2013;66:346-56
52. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48:954-62
53. Clark SA, Martin SL, Pozniak A, Steel A, Ward B, Dunning J, et al. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007;150:238-44
54. Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, et al. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-gamma release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis 2011;69:59-65
55. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180:49-58
56. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831-9
57. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-6
58. Richeldi L, Ewer K, Losi M, Bergamini BM, Millington K, Fabbri LM, et al. T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. Pediatrics 2007;119:e1-5
59. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. Ann Rheum Dis 2012;71:231-7
60. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of QuantiFERON-TB gold in-tube assay. Clin Vaccine Immunol 2008;15:425-32
61. Harada N, Mori T, Shishido S, Higuchi K, Sekiya Y. Usefulness of a novel diagnostic method of tuberculosis infection, QuantiFERON TB-2G, in an outbreak of tuberculosis. Kekkaku 2004;79:637-43
62. Davidow AL, Affouf M. Making sense of agreement among interferon-gamma release assays and tuberculosis skin testing. Int J Tuberc Lung Dis 2008;12:152-9
63. Vesenbeckh SM, Schonfeld N, Mauch H, Bergmann T, Wagner S, Bauer TT, et al. The use of interferon gamma release assays in the diagnosis of active tuberculosis. Tuberc Res Treat 2012;2012:768723
64. Harada N, Higuchi K, Sekiya Y, Rothel J, Kitoh T, Mori T. Basic characteristics of a novel diagnostic method (QuantiFERON TB-2G) for latent tuberculosis infection with the use of Mycobacterium tuberculosis-specific antigens, ESAT-6 and CFP-10. Kekkaku 2004;79:725-35
65. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay. Ann Rheum Dis 2012;71:231-7
66. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 2009;16:1203-12
67. Ottenhoff TH. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int J Tuberc Lung Dis 2012;16:1424-32
68. Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL, Drijfhout JW, et al. Double- and monofunctional CD4(+) and CD8(+) T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 2011;41:2925-36
69. Commandeur S, van Meijgaarden KE, Lin MY, Franken KL, Friggen AH, Drijfhout JW, et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. Clin Vaccine Immunol 2011;18:676-83
70. Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, Palmieri F, et al. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med 2003;9:105-11
71. Goletti D, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J Infect 2010;61:133-43
72. Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, Carrara S, et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One 2010;5:e12577
73. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007;8:5
74. Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004;38:754-6
75. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis 2008;8:11
76. Kabeer BS, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011;11:135
77. Latorre I, Altet N, de Souza-Galvao M, Ruiz-Manzano J, Lacoma A, Prat C, et al. Specific Mycobacterium tuberculosis T cell responses to RD1-selected peptides for the monitoring of anti-tuberculosis therapy. Scand J Infect Dis 2012;44:161-7
78. Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, Wickremasinghe M, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 2011;108:5730-5
79. Wayne LG. In vitro model of hypoxically induced nonreplicating persistence of Mycobacterium tuberculosis. Methods Mol Med 2001;54:247-69
80. Wayne LG, Hayes LG. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuber Lung Dis 1998;79:127-32
81. Yuan Y, Crane DD, Barry CE 3rd. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 1996;178:4484-92
82. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003;48:833-43
83. Goletti D, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010;36:135-42
84. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006;8:2052-60
85. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KL, et al. Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. PLoS One 2009;4:e5590
86. Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One 2011;6:e27539
87. Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua A, et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One 2011;6:e18315
88. Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, Locht C, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 2007;176:409-16
89. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verscheure V, et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2007;2:e926
90. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008;32:1607-15
91. Ruhwald M, Petersen J, Kofoed K, Nakaoka H, Cuevas LE, Lawson L, et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 2008;3:e2858
92. Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012;65:49-59
93. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, et al. Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect 2010;16:1282-4
94. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O'rie T, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 2011;187:2222-32
95. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011;17:372-6
96. Sester U, Fousse M, Dirks J, Mack U, Prasse A, Singh M, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One 2011;6:e17813
97. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, et al. Mycobacterium tuberculosis-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease. Eur J Immunol 2013;43:1568-77
98. Schuetz A, Haule A, Reither K, Ngwenyama N, Rachow A, Meyerhans A, et al. Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo. PLoS One 2011;6:e27284